|Place of Origin:||China|
|Certification:||ISO9001 , KOSHER , SGS|
|Model Number:||CAS 863288-34-0|
|Minimum Order Quantity:||Negotiation|
|Packaging Details:||10g/50g/100g/500g/1000g/foil bag and 25kg/drum|
|Delivery Time:||Within 24h after confirming the payment|
|Payment Terms:||T/T, Western Union, MoneyGram, Bitcoin|
|Supply Ability:||1000kg per month|
|Product Name:||CJC1295||Usage:||Increase GH Production|
|Molecular Formula:||C159H258N46O45||Appearance:||White Powder|
|Assay:||99%||Storage:||Protect Sun Damage And 2-8 Degrees Cel|
Body Building Peptides CAS 863288-34-0 CJC-1295 for Increase GH Production
|Product Name||CJC-1295 Acetate|
|Amino Acid Composition||10% of theoretical|
|Peptide Content(N%)||80%(by %N)|
|Water Content(Karl Fischer)||6.0%|
CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a releasing hormone (GHRH) analog.
One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects.
CJC-1295 is a tetrasubstituted peptide analogue of GHRH with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide with the substitution at position 2 to prevent DPP-IV cleavage, position 8 to reduce asparagine rearrangement or amide hydrolysis to aspartic acid, position 15 to enhance bioactivity, and position 27 to prevent methionine oxidation. These substitutions are key in increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended from ~7 minutes to greater than 7 days! Bioconjugation is a relatively newer technology that takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond. Albumin, one of the most abundant substances in the human body is chosen as the nucelophile by this particular peptide thanks to a Cys34 thiol group that attracts it. By combining the tetrasubstituted GHRH analogue with maleimodoproprionic acid using a Lys linker, you create a GHRH peptide with a high binding affinity for albumin. Once the CJC-1295 molecule has attached itself to albumin, it is given an extended half life and bioavailability thanks to the albumin preventing enzymatic degredation and kidney excretion. In fact, bioconjugation is so effective that there was less than 1% of CJC-1295 left unreacted in vivo and over 90% was stabilized after subQ admin. This means that you get more of what you paid for working for you. There was no DPP-IV degredation observed on CJC-1295 in any of the various experiments conducted.
Due to the extremely long half life of CJC-1295 it is plausible for researchers to use this peptide once per week with outstanding results. Various experiments have been conducted to test the effectiveness of CJC-1295 in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased concentrations 1.5-3 fold for 9-11 days after a single injection! Not only that but they proved the mean half life to be 5.8-8.1 days and after multiple doses showed mean levels remained above baseline for up to 28 days following! No serious adverse reactions were reported in any group.
CJC-1295 acts for much longer than pure GRF. It acts on the pituitary gland and keeps stimulating the release of growth hormone in pulses. The reason why it acts in pulses is because the axis of the human growth hormone controls how much of the hormone can remain in the body at a time. This maintains the homeostatic environment in the body.
The DAC technology in the CJC-1295 enables the compound to bind itself covalently with any circulating albumin, after it has been administered through a subcutaneous injection. However, the reason why the half-life could be extended from a few minutes to several days is more profound. The reactive group in the CJC-1295 binds to a peptide through bioconjugation. The peptide then finds a neucleophilic unit within the blood and reacts with it in order to create a firmer bond.
When using any GHRH, it should always be remembered that positive results cannot be achieved overnight. These compounds act steadily over time, and the best results can be achieved slowly, and with a nutritious diet and a proper exercise regime. Also, these peptides are not sex-specific, so they do not have any androgenic effects. They can be used by women in the same dosages that men do.
CJC 1295 is typically provided in vials containing 2 or 5 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.
At time of dosing, an insulin syringe is used to draw and then inject the desired amount. In the above example, a 1000 mcg dose would require a volume of 1 mL, or “100 IU” as marked on an insulin syringe.
Injection may be subcutaneous, intramuscular, or intravenous according to personal preference. If desired, peptide solutions from other vials, such as a vial of a GHRP product, may also be drawn into the same syringe, if there is room. This reduces the total number of injections required.when recommending CJC 1295, I ordinarily recommend a dosage of 1000 mcg at a time, twice per week.
Contact Person: Mr. Dr. Zhang